Building a Portfolio of High Impact New Medicines

AMO Pharma's investigational drugs currently in development include:

•	AMO-01 for the treatment of Phelan-McDermid Syndrome.
•	AMO-02 for the treatment of congenital myotonic dystrophy.
•	AMO-04 for the treatment of Rett syndrome.